RT @doctorRBC: 52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improve
Tweet Content
52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores.
Synovial hypertrophy most responsive.
Hands and feet, wrist and knees most affected and responsive.
@RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa
Show on Archive Page
On
Display in Search Results
On
PDQ
Off